Want to see KR:004720 full AI Analyst Report?
PharmGen Science, Inc. (004720) Income Statement
PharmGen Science, Inc. Income Statement
Last quarter (Q2 2026), PharmGen Science, Inc.'s total revenue was $47.72B, an increase of 4.02% from the same quarter last year. In Q2, PharmGen Science, Inc.'s net income was $-13.58B. See PharmGen Science, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 173.07B | $ 171.29B | $ 166.78B | $ 150.93B | $ 109.87B | |
| $ 109.13B | $ 108.03B | $ 96.20B | $ 81.30B | $ 60.80B | |
| $ 103.15B | $ 97.39B | $ 87.07B | $ 73.82B | $ 64.10B | |
| Depreciation and Amortization | $ 4.56B | $ 4.64B | $ 4.25B | $ 3.37B | $ 3.14B |
| $ 10.53B | $ 10.79B | $ 13.37B | $ 10.78B | $ -254.11M | |
| $ 5.99B | $ 10.64B | $ 9.13B | $ 9.32B | $ -4.94B | |
| $ -157.09B | $ -9.63B | $ -1.14B | $ 82.49B | $ 46.99B | |
| $ -151.10B | $ 1.02B | $ 7.99B | $ 89.96B | $ 41.95B | |
| $ -116.64B | $ 2.79B | $ 5.73B | $ 70.06B | $ 32.47B | |
| Per Share Metrics | |||||
| Basic EPS | $ -5312.85 | $ 154.07 | $ 374.00 | $ 4498.10 | $ 2206.02 |
| Diluted EPS | $ -5312.85 | $ 152.25 | $ 324.00 | $ 3369.29 | $ 1814.33 |
| Weighted Average Shares Outstanding | 21.95M | 18.14M | 16.28M | 15.57M | 14.72M |
| Weighted Average Shares Outstanding (Diluted) | 21.95M | 21.78M | 20.80M | 21.59M | 18.60M |
Currency in KRW
